1 documents found
Information × Registration Number 0221U104838, 0120U002186 , R & D reports Title Optimization of conservative treatment of HER2 / neu breast cancer patients (negative) at high risk of disease progression. popup.stage_title Head Syvak Lubov А., Доктор медичних наук Registration Date 25-04-2021 Organization National Cancer Institute popup.description2 The object of the study - 135 patients with metastatic breast cancer, 65 patients with luminal B RGD and 70 - with three times negative RGD. When studying the features of lymphoid infiltration of tumor tissue in patients with three times negative RGD, it was found that high levels of peritumoral CD4 + lymphocytes at the time of diagnosis increases the risk of metastasis in patients with three times negative RGD by an average of 1.73 times (HR 1.73; 95% VI 1.27 - 2.37; p <0.001), instead, a high level of FOXP3 + lymphocytes in the immune infiltrate at the time of diagnosis indicates a decrease in the likelihood of recurrence (HR 0.66; 95% CI 0.50 - 0.88; p = 0.005) in patients with three times negative RGD. The risk of death from RGD was found to be different in patients with different ratios of CD8 + lymphocytes and FOXP3 + lymphocytes. In patients with metastatic RGD of prognostically unfavorable molecular subtypes, the ratio of circulating lymphocytes expressing activation markers CD95 and HLA-DR corresponds to that in PHD. In contrast, patients with luminal B Her2 / neu negative RGD are characterized by a decrease in the relative number of CD25 + cells among peripheral blood lymphocytes. Decreased ITSN2 mRNA expression was detected in tumors with an unfavorable diagnosis (ER +/– PR +/– HER2 / neu +). Decreased expression was observed in the total number of ITSN2 isoforms and separately the short isoform (ITSN2-S). This suggests the possibility of using ITSN2-S as a prognostic marker of the breast. No significant differences in the expression of ITSN2-L and TKS5-L in the analyzed samples were found. Product Description popup.authors Verovkina Nataliia O. Dasiukevich Olga Y. Lyalkin Sergey A. Martynyuk Olena M Orel Valeriy E. Rykhalskyy Oleksandr Yu Tarasenko Tetyana Y. Filchakov Feodosiy V. Yatsenko Lyudmyla D. popup.nrat_date 2021-04-25 Close
R & D report
Head: Syvak Lubov А.. Optimization of conservative treatment of HER2 / neu breast cancer patients (negative) at high risk of disease progression.. (popup.stage: ). National Cancer Institute. № 0221U104838
1 documents found

Updated: 2026-03-26